SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Outrageous prices of orphan drugs: a call for collaboration
3 references·2 citing·18 second hop
Outrageous prices of orphan drugs: a call for collaboration (2018)Outrageous prices of orphan drugs: a call…The Price of Inequality: How Today's Divided Society Endangers Our Future (2015)The Price of Inequality: How …The $2.6 Billion Pill — Methodologic and Policy Considerations (2015)The $2.6 Billion Pill — Metho…Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? (2012)Paying for the Orphan Drug Sy…Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications (2021)Potential approaches for the …Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis (2020)Access and Unmet Needs of Orp…Priority setting of health interventions: the need for multi-criteria decision analysis. (2006)Assessing the economic challenges posed by orphan drugs (2007)Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers (2007)A Pilot Study of Multicriteria Decision Analysis for Valuing Orphan Medicines (2013)Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets (2018)A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries (2020)What does 'access to health care' mean? (2002)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. (2009)The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts (2013)Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13 (2017)Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3] (2018)Redistribution, Inequality, and Growth (2014)Linking Economic Complexity, Institutions, and Income Inequality (2017)Defining and conceptualising the commercial determinants of health (2023)How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries (2017)Financial toxicity and implications for cancer care in the era of molecular and immune therapies (2018)Pricing of pharmaceuticals is becoming a major challenge for health systems (2020)
this work references cited by second hop

References

  • 2015The Price of Inequality: How Today's Divided Society Endangers Our Future2,935 cited
  • 2015The $2.6 Billion Pill — Methodologic and Policy Considerations319 cited
  • 2012Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?171 cited

Cited by

  • 2020Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis103 cited
  • 2021Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications75 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work